According to preliminary results, the Covit-19 vaccine administered by Sanofi and GlaxoSmithKline has been shown to be effective as a booster vaccine in one study. The simple booster with the vaccine developed strong immunity, both companies announced Wednesday.
According to preliminary data, the booster vaccine showed a nine to 43-fold increase in neutralizing antibodies, regardless of the vaccine previously obtained (AstraZeneca, Johnson & Johnson, Moderna, Pfizer / BioNTech) and tested age. The vaccine is well tolerated and has the same safety profile as currently approved vaccines.
The ongoing Phase 3 study to gather more data is expected to continue until the beginning of next year. Results are expected in the first quarter. “These initial data show that we have a strong booster candidate, regardless of which primary vaccine you receive,” said Thomas Triumph, executive vice president of vaccination subsidiary Sanofi Pasteur.
Considering the strong competition from Biontech / Pfizer and Moderna, Sanofi withdrew from developing his own mRNA vaccine against Kovit-19 at the end of September. The French focused on their protein-based vaccine, which was developed by Sanofi GlaxoSmithKline. The company expanded its development program to include the study of the vaccine as a booster dose.
Harper Lee is a contributor to Columbus Post, covering a broad range of topics including news, politics, business, technology, sports, entertainment, and lifestyle. With a focus on clear reporting and useful information, Harper Lee follows current events and developments that matter to readers. Her work aims to present accurate, accessible coverage and thoughtful updates, helping audiences stay informed about important issues, emerging trends, and stories shaping communities and everyday life.
More Stories
Why OpenAI Is Selling a ChatGPT Basketball Alongside Its New Hardware Launch
OpenAI Moves to Eliminate “Goblin Talk” From ChatGPT Models
Video Appears to Show U.S. Cruise Missile Striking Iranian School Compound